Biofrontera (STU:AI10) Other Long-Term Liabilities: €0.46 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AI10 Biofrontera Inc STU:AI10
38 GF Score
Price €8.06
GF Value €2.83
! 6 Warning Signs
View Full Analysis

What is Biofrontera Other Long-Term Liabilities?

Biofrontera STU:AI10 38 Other Long-Term Liabilities is €0.46 Mil as of Jun. 2026. GuruFocus rates STU:AI10 with a GF Score™ of 38/100 and a GF Value™ of €2.83. The stock has 6 warning signs investors should review.

Biofrontera's other long-term liabilities for the quarter that ended in Jun. 2026 was €0.46 Mil.

Biofrontera's quarterly other long-term liabilities increased from Dec. 2025 (€0.31 Mil) to Mar. 2026 (€0.50 Mil) but then declined from Mar. 2026 (€0.50 Mil) to Jun. 2026 (€0.46 Mil).

Biofrontera's annual other long-term liabilities declined from Dec. 2023 (€3.89 Mil) to Dec. 2024 (€1.22 Mil) and declined from Dec. 2024 (€1.22 Mil) to Dec. 2025 (€0.31 Mil).

Biofrontera Other Long-Term Liabilities Related Terms

Biofrontera Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Biofrontera's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera Other Long-Term Liabilities Chart

Biofrontera Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial 16.38 2.70 3.89 1.22 0.31

Biofrontera Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.72 0.31 0.50 0.46
STU:AI10
38GF Score
Biofrontera Inc STU:AI10
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofrontera Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €0.46 Mil mean?
Biofrontera (STU:AI10) has a Other Long-Term Liabilities of €0.46 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Biofrontera and its competitors.
Is Biofrontera's Other Long-Term Liabilities too high?
Biofrontera's current Other Long-Term Liabilities is €0.46 Mil. Overall, Biofrontera has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera's Other Long-Term Liabilities compare to HYEX and CABR?
Biofrontera's Other Long-Term Liabilities of €0.46 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Biofrontera and its competitors. Biofrontera's current Other Long-Term Liabilities is €0.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera stock overvalued right now?
Biofrontera (STU:AI10) has a current Other Long-Term Liabilities of €0.46 Mil. The stock's GF Value™ is €2.83, compared to a current price of €8.06 — trading 184.8% above its estimated fair value. The current Other Long-Term Liabilities is €0.46 Mil. Biofrontera's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Biofrontera (STU:AI10), the current Other Long-Term Liabilities is €0.46 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera (STU:AI10) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued. The current stock price of €8.06 is trading 184.8% above its estimated GF Value™ of €2.83.

Key valuation signals for STU:AI10:

  • Other Long-Term Liabilities: €0.46 Mil
  • GF Value™: €2.83 vs. price of €8.06 (184.8% above fair value)
  • GF Score™: 38/100 with 6 warning signs

No single metric tells the full story. See the STU:AI10 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera Business Description

Other Exchanges BFRI:USA
Address 660 Main Street, 1st Floor, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
38GF Score

Get the complete analysis for STU:AI10

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.06
Price
€2.83
GF Value